Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

被引：0
|
作者：
Garcia-Garcia, C. [1 ]
Ibrahim, Y. H. [1 ]
Serra, V. [1 ]
Calvo, M. T. [1 ]
Aura, C. [1 ]
Perez, J. [1 ]
Rommel, C. [2 ]
Tabernero, J. [1 ]
Baselga, J. [3 ]
Scaltriti, M. [3 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Intellikine Inc, La Jolla, CA USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)71437-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
804
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [41] Effect of pan-PI3K and HER2 blockade on antitumor activity in preclinical models of breast cancer resistance to trastuzumab therapy.
    De, Pradip
    Sun, Yuliang
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models
    Kavuri, S. M.
    Devarakonda, V.
    Williams, L. C.
    Seker, S.
    Lei, J. T.
    Singh, P.
    Han, A.
    Anurag, M.
    Holloway, K. R.
    Welm, A. L.
    Ellis, M. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma
    Jiang, Haibin
    Zeng, Zhiyuan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 468 (1-2) : 255 - 261
  • [44] Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models
    Devarakonda, Vaishnavi
    Williams, LaTerrica
    Seker, Sinem
    Lei, Jonathan T.
    Singh, Purba
    Han, Airi
    Anurag, Meenakshi
    Holloway, Kimberly R.
    Weim, Alana L.
    Ellis, Matthew J.
    Kavuri, Shyam M.
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Dual HER2 Blockade
    Thomssen, Christoph
    El Saghir, Nagi S.
    Francis, Prudence A.
    Jassem, Jacek
    Rugo, Hope S.
    Untch, Michael
    BREAST CARE, 2017, 12 (05) : 345 - 349
  • [46] The combination of Talazoparib with anti-her2 drugs shows efficacy in drug resistant Her2+and low Her2 PDX models
    Bozek, Kathryn
    Buchanan, Marguerite
    Lan, Cathy
    Lafleur, Josiane
    Darini, Cedric
    Krzemien, Urszula
    Aguilar-Mahecha, Adriana
    Basik, Mark
    CANCER RESEARCH, 2022, 82 (12)
  • [47] Prospect for anti-HER2 receptor therapy in breast cancer
    Brand, FX
    Ravanel, N
    Gauchez, AS
    Pasquier, D
    Payan, R
    Fagret, D
    Mousseau, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 463 - 470
  • [48] Anti-HER2 therapy for breast cancer in older patients
    Goldner, Marcelle
    Franzoi, Maria A.
    Lago, Lissandra D.
    Ponde, Noam
    FUTURE ONCOLOGY, 2020, 16 (19) : 1393 - 1407
  • [49] Anti-HER2 Therapy in Elderly Breast Cancer Patients
    Sawaki, Masataka
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (04) : 263 - 266
  • [50] Current and future anti-HER2 therapy in breast cancer
    Vrbic, S.
    Pejcic, I.
    Filipovic, S.
    Kocic, B.
    Vrbic, M.
    JOURNAL OF BUON, 2013, 18 (01): : 4 - 16
12345